Biofisica develops and markets products for soft tissue wound healing and tissue regeneration based on an exclusive and technology that uses electrical stimulation and hydro-gel materials.
Latest Biofisica News
May 23, 2016
Login Biofisica Raises $2 Million ATDC member company Biofisica , an innovator in wound care therapy, has raised $2 million in venture debt financing from Leader Ventures . Biofisica plans to use the capital to continue funding its pioneering wound care product, POSiFECT. The product was launched in early 2007 and is now being marketed and sold in the United Kingdom. Biofisica has filed an application for 510(k) approval with the FDA to receive clearance to market its products in the United States. “We are pleased that Leader Ventures has chosen to support our business model as we move forward with this important product in the field of wound care management,” said Rafael Andino, president and CEO of Biofisica. “This new infusion of capital supports our efforts to establish POSiFECT as a premier product in the wound care market and demonstrates Biofisica’s ability to attract high caliber investment partners.”
Biofisica Frequently Asked Questions (FAQ)
When was Biofisica founded?
Biofisica was founded in 1999.
Where is Biofisica's headquarters?
Biofisica's headquarters is located at 6455 East Johns Crossing, Duluth.
What is Biofisica's latest funding round?
Biofisica's latest funding round is Unattributed VC.
How much did Biofisica raise?
Biofisica raised a total of $9.3M.
Who are the investors of Biofisica?
Investors of Biofisica include Advanced Technology Development Center, Novartis Venture Funds, Unilever Ventures, Leader Ventures, Seed Capital Fund of CNY and 3 more.
Who are Biofisica's competitors?
Competitors of Biofisica include Adhezion Biomedical, Regentis Biomaterials, FirstString Research, OcuNexus Therapeutics, Histogenics and 7 more.
Compare Biofisica to Competitors
Nanotope is a regenerative medicine company that leverages a core set of technologies to address multiple therapeutic markets. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for wound healing and the treatment of peripheral artery disease.n
OcuNexus Therapeutics is a clinical-stage company focused on the healthcare sector, specifically in the development of treatments for diseases where the inflammasome pathway of inflammation is dysregulated. The company's main product is a small molecule, administered orally once a day, that targets the pathologically open Connexin43 Hemichannel, which is responsible for inflammasome mediated autoinflammation in several disease states. The company primarily sells to the ophthalmology and nephrology sectors, with a focus on conditions such as diabetic retinopathy, diabetic nephropathy, and the intermediate stage of macular degeneration. OcuNexus Therapeutics was formerly known as CoDa Therapeutics. It was founded in 2005 and is based in San Diego, California.
AugmentRx has developed a tissue bulking agent to treat stress urinary incontinence. The SOLVE injectable product aims to provide a fully viable alternative to slings, surgical procedures and inferior shorter-acting bulking agents. Per AugmentRx, it is bioinert, non-antigenic, non-migratory, permanent, easy-to-inject, and more affordable and aims to provide long-lasting, sustainable tissue volume.
Isolating diverse creatures including species indegenous to rainforests in Malaysia, exploring new compounds which lead development of new medicine conforming to CBD and building a predominant bio-resource collection, NGS will contribute to health and progress of bioindustries in international community.
FirstString is a biopharmaceutical company dedicated to discovering therapies for inflammation-based medical conditions.
PluroGen Therapeutics provides clinically advanced and advantaged burn, wound and skin care products. The company works closely with doctors, nurses, patients and healthcare institutions to provide the best products for burn, wound and skin care to help people have a better quality of life. The Company's primary platform is its core PluroGel surfactant technology which provides products with paradigm-shifting, superior and differentiated Core, Bio-Physical, and Performance Functions resulting in unique and advantaged Multi-Function products.